Apellis Pharmaceuticals has announced US FDA acceptance of the supplemental new drug application (sNDA) and the granting of ...

Apellis' Empaveli receives FDA Priority Review for rare kidney diseases C3G and IC-MPGN. Phase 3 data show strong efficacy in proteinuria reduction.

Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has accepted and granted Priority Review designation ...

In the United States, the market has experienced a 3.5% decline over the last week, yet it remains up by 5.8% over the past year with earnings expected to grow annually by 14%. In this context of ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) has received an average recommendation of “Moderate Buy” from ...

Here is our list of the 11 Best Gene Therapy Stocks to Buy According to Analysts.

The current state of treatment for geographic atrophy is marked by two approved therapies that slow GA progression: ...

In a report released today, Francois Brisebois from Oppenheimer maintained a Buy rating on Tarsus Pharmaceuticals (TARS – Research Report), ...